Baclofen and gamma-hydroxybutyrate withdrawal (2008)

[Jatelka]

A new entry has been added to File Archive

Description:
Neurocritical Care 2008;8(3):430-3

LeTourneau JL, Hagg DS, Smith SM.

INTRODUCTION: Benzodiazepine treatment of life-threatening gamma-hydroxybutyrate (GHB) withdrawal is frequently unsatisfactory. Animal studies suggest strongly that treatment with GABA(B) agonists, such as baclofen, will be a more effective strategy.

METHODS: A case report from the medical intensive care unit (ICU) of the university tertiary care hospital.

RESULTS: A 61-year-old woman was admitted to the medical ICU for severe withdrawal symptoms from chronic GHB use. This manifested as delirium, tremor, and seizures despite only small decreases in GHB dose and treatment with benzodiazepines. The addition of baclofen allowed the rapid sequential decreases in the GHB dose without seizure or delirium and resulted in long-term improvement of her tremor.

CONCLUSIONS: Baclofen, a GABA(B) agonist, may be a useful agent in the treatment of severe GHB withdrawal.

To check it out, rate it or add comments, visit Baclofen and gamma-hydroxybutyrate withdrawal (2008)
The comments you make there will appear in the posts below.